id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307858-274a699i	Hotez, Peter J.	COVID-19 vaccines: neutralizing antibodies and the alum advantage	2020-06-04		.txt	text/plain	1331	64	40	A chemically inactivated virus vaccine (PiCoVacc) and a recombinant proteinbased vaccine (CoV-RBD219N1) were recently shown to elicit high levels of protective immunity in rhesus macaques or in mice against homologous virus challenge with SARS-CoV-2 or SARS-CoV, respectively 2,3 . Similarly, mice vaccinated with CoV-RBD219N1, based on the recombinant RBD protein of SARS-CoV, which is now investigated as a COVID-19 vaccine candidate, exhibited virus-neutralizing antibody titres between 640 and 1,280 upon SARS-CoV homologous viral challenge 3 . Therefore, an emerging story in COVID-19 vaccine development is the potential importance of inducing high levels of neutralizing antibodies to the S protein or its RBD. A key finding so far is that aluminium adjuvant formulations, such as those used for PiCoVacc and CoV-RBD219N1, appear to promote high titres of neutralizing antibody. A potential concern about the use of aluminium adjuvants is based on the claim that T H 2-type immune responses might promote vaccine-enhanced respiratory disease (VAERD) 9 .	./cache/cord-307858-274a699i.txt	./txt/cord-307858-274a699i.txt